home · filing · 0001140361-25-000708
8-K filed January 10, 2025, 6:59 PM ET
CIK 0001840904
leadership
confidence high
sentiment neutral
materiality 0.60
atai appoints Srinivas Rao as sole CEO, Gerd Kochendoerfer as COO, promotes Kevin Craig to CMO and Glenn Short to CSO
ATAI Life Sciences N.V.
Dr. Srinivas Rao becomes sole CEO effective Jan 1, 2025, after co-CEO transition.
Gerd Kochendoerfer appointed COO effective Dec 3, 2024, from NFlection Therapeutics.
Kevin Craig promoted to CMO leading VLS-01 and EMP-01 Phase 2 trials; Glenn Short named CSO.
VLS-01 now screening patients; Phase 2b data for BPL-003 (Beckley Psytech) expected mid-2025.
Dr. Rao receives $629,200 base salary, 55% bonus target, and option for 2.34M shares.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Role change
Srinivas Rao
Chief Executive Officer
ATAI Life Sciences N.V.
Effective 2025-01-01
Filed January 10, 2025, 6:59 PM ET
Dr. Srinivas Rao will serve as the Company’s sole Chief Executive Officer and principal executive officer, effective January 1, 2025.
Effective 2024-12-31
Successor Srinivas Rao
Filed January 10, 2025, 6:59 PM ET
Florian Brand stepped down as Co-Chief Executive Officer and member of the Company’s management board as of December 31, 2024.
Appointed
Gerd Kochendoerfer
Chief Operating Officer
ATAI Life Sciences N.V.
Effective 2024-12-03
Filed January 10, 2025, 6:59 PM ET
the Board appointed Dr. Gerd Kochendoerfer as the Company’s Chief Operating Officer, effective December 3, 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Srinivas Rao was appointed as Chief Executive Officer at ATAI Life Sciences N.V..
Action appointed
Role Chief Executive Officer
Exact text from the filing
Dr. Srinivas Rao will serve as the Company’s sole Chief Executive Officer and principal executive officer, effective January 1, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Florian Brand departed as Co-Chief Executive Officer at ATAI Life Sciences N.V..
Action stepped down
Role Co-Chief Executive Officer
Exact text from the filing
Florian Brand stepped down as Co-Chief Executive Officer and member of the Company’s management board as of December 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gerd Kochendoerfer was appointed as Chief Operating Officer at ATAI Life Sciences N.V..
Action appointed
Role Chief Operating Officer
Exact text from the filing
the Board appointed Dr. Gerd Kochendoerfer as the Company’s Chief Operating Officer, effective December 3, 2024.
View on SEC.gov
Source: SEC EDGAR
accession 0001140361-25-000708
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.